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Abstract
Neuromyelitis optica (NMO) is a severe, debilitating human disease that predominantly features
immunopathology in the optic nerves and the spinal cord. An IgG1 autoantibody (NMO-IgG) that
binds aquaporin 4 (AQP4) has been identified in the sera of a significant number of NMO patients,
as well as in patients with two related neurologic conditions, bilateral optic neuritis (ON), and
longitudinal extensive transverse myelitis (LETM), that are generally considered to lie within the
NMO spectrum of diseases. NMO-IgG is not the only autoantibody found in NMO patient sera,
but the correlation of pathology in central nervous system (CNS) with tissues that normally
express high levels of AQP4 suggests NMO-IgG might be pathogenic. If this is the case, it is
important to identify and understand the mechanism(s) whereby an immune response is induced
against AQP4. This review focuses on open questions about the "events" that need to be
understood to determine if AQP4 and NMO-IgG are involved in the pathogenesis of NMO. These
questions include: 1) How might AQP4-specific T and B cells be primed by either CNS AQP4 or
peripheral pools of AQP4? 2) Do the different AQP4-expressing tissues and perhaps the membrane
structural organization of AQP4 influence NMO-IgG binding efficacy and thus pathogenesis? 3)
Does prior infection, genetic predisposition, or underlying immune dysregulation contribute to a
confluence of events which lead to NMO in select individuals? A small animal model of NMO is
essential to demonstrate whether AQP4 is indeed the incipient autoantigen capable of inducing
NMO-IgG formation and NMO. If the NMO model is consistent with the human disease, it can be
used to examine how changes in AQP4 expression and blood-brain barrier (BBB) integrity, both of
which can be regulated by CNS inflammation, contribute to inductive events for anti-AQP4-specific
immune response. In this review, we identify reagents and experimental questions that need to be
developed and addressed to enhance our understanding of the pathogenesis of NMO. Finally,
dysregulation of tolerance associated with autoimmune disease appears to have a role in NMO.
Animal models would allow manipulation of hormone levels, B cell growth factors, and other
elements known to increase the penetrance of autoimmune disease. Thus an AQP4 animal model
would provide a means to manipulate events which are now associated with NMO and thus
demonstrate what set of events or multiplicity of events can push the anti-AQP4 response to be
pathogenic.
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Introduction
Neuromyelitis optica (NMO)
There are many excellent reviews on the clinical and laboratory aspects of NMO, reviews that describe criteria for
diagnosis, and paraclinical features of NMO and the
NMO spectrum of disorders [1-5]. We do not intend this
to be a review of these issues. There is a complex, diverse
array of "preceding environmental events" and perhaps
unconnected immune-related events which are often
associated with the period before patients are diagnosed
with NMO. In this review we discuss in detail how the different isoform structures of AQP4 in different membrane
locales and in different cell types might be related to
pathology. Changes in AQP4 expression in CNS and nonCNS tissue can be regulated by inflammatory mediators
induced during and following infection or by underlying
autoimmunity and can result in the induction of AQP4specific lymphocytes and ensuing pathogenesis.

NMO is a devastating disease affecting primarily young
women (relapsing NMO) but either sex can develop
monophasic NMO, and NMO rarely occurs in adolescents. The disease principally attacks the optic nerves and
spinal cord causing blindness and paralysis. The most
notable difference between NMO and multiple sclerosis
(MS) is the lower frequency of brain lesions in NMO,
especially early in the disease [6]. An autoantibody (IgG1)
that binds AQP4 has been found in a high percentage
(~75%) of NMO patients (NMO-IgG) [7]. NMO patients
that do not have detectable levels of NMO-IgG1 may represent a group for which AQP 4 is not the target antigen
for autoantibody. Other CNS antigens such as the Kir4.1
present on astrocytes might be targets for autoantibodies
in those NMO patients. It is possible that there is a unique
and rare specificity of NMO-IgG1 that is particularly pathogenic but that can not be detected by current diagnostic
techniques – mouse tissue to screen NMO sera. Clearly to
address these issues the NMO-IgG1 concentration,
epitope specificity, and affinity need to be better categorized at the initial presentation and during the patient's
response to treatment.
Other autoantibodies have been found in NMO patient
sera and CSF, including antinuclear antibodies, SS antibodies [8] and in particular anti-myelin oligodendrocyte
glycoprotein (MOG) antibodies [9,10]. Other antibodies
specific for extra- or intracellular antigens (myelin basic
protein, S100β, CPSF-73, RNF-141, and myosin light
chain are also present in some NMO patients. These latter
autoantibodies likely represent a response to neo-antigen
liberated from dead cells and thus are not the initial cause
of NMO but could be involved in the pathogenesis of
recurrent disease via a type III hypersensitivity reaction
[9,11]. Consistent with the potential role of a humoral
response in NMO pathogenesis is the perivascular deposi-

http://www.jneuroinflammation.com/content/5/1/22

tion of IgM and IgG, both of unknown specificity. In addition, the terminal products of complement (C9)
activation are found with antibody depositions in spinal
cord lesions of NMO patients [12].
AQP4 a transmembrane protein important for CNS
function
Aquaporin 4 is a type III transmembrane protein (intracellular n- and c-termini) that regulates water entry into
and out of specific cells in the brain and interfaces with
blood vessels within the neuropil and around the ventricles. The AQPs and the aquaglyceroporin mammalian
family contains at least 12 members that are involved in
water and/or glycerol transport [13] but AQP4 is the predominant water channel in the brain of humans and
rodents. The more than 200 different AQP-like
"sequences" expressed by diverse organisms underscores
the importance of this protein family [14]. AQP4 regulates water mostly in multiple types of tissue epithelia, but
it also has a critical role when expressed by astrocytes
which regulate water and ion movement in parts of the
brain.

The expression pattern of AQP4 protein is most well characterized for rats which express AQP4 in multiple tissues
and in specific cell populations in particular tissues (Table
1). In humans, expression of AQP4 in the brain, spinal
cord, and optic nerves is associated with astrocyte membranes that closely appose endothelial cell basal membranes. It is of note that astrocytes interact extensively
with endothelial cells to maintain the CNS BBB, which
normally limits the access of immune system effectors
unless localized or distant events disrupt the BBB, thus
allowing access of cellular or soluble immune effectors.
The BBB is maintained by active interactions between
astrocytes and endothelial cells. There are regions in the
brain that lack these close interaction based on anatomical organization of the two cell types, and in these areas
the BBB is compromised. These regions include termini of
peripheral nerves (olfactory), sensory ganglia (spinal and
cranial nerves), and the optic nerves. Some ependyma and
some capillaries in the CNS lack continuous endothelia
with tight junctions [15].
AQP4 is expressed in astrocytes in the neocortex, hippocampus, cerebellum and many circumventricular structures including the glial lamellae of the supraoptic
nucleus and the subfornical osmosensory organ of the
brain [16]. The microvessels of the subfornical organ have
a caudal to rostral difference in the BBB due to the distinct
association of astrocytes with endothelial cells at different
parts of this organ [17]. AQP4 is also expressed in a subpopulation of CNS ependymal cells associated with the
pia, subfornical organ, and to a lesser extent in other
ependyma but not in the choroid plexus. In the hypotha-
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Table 1: Tissues with AQ4 expression organized via biological system.

System Animal (references)

AQ4-Positive Tissues
(Detection Methods)a

Positive Cell Types

Cellular
Localization

Expression Pattern

Nervous human [68, 135]
mouse [136, 137] Rat [16, 19,
55, 135, 138–140]

Gray and White Matter (IHC,
IEM)

Astrocytes

Perivascular End-Feet

Orthogonal Arrays

Ventricles, but not in Choroid
Plexus (IHC, IEM)
Pia Mater (IHC)
Retina (ISH, IF, IEM)

Ependymal Cells

Basolateral

Orthogonal Arrays

Meningeal Cells
Müller Cells Astrocytes

N.Db
Vitreal End-Feet
Perivascular End-Feet
Perivascular End-Feet

N.D.
N.D.
N.D.

Hensen's Cells Inner Sulcus
Cells Supporting Cells of
the Vestibular End Organ
Epithelial Cells

Basolateral

N.D.

Basolateral

Orthogonal Arrays

Columnar Epithelial Cells
Intermediate cells
Epithelial Cells

Basolateral

N.D.

N.D.

N.D.

Epithelial Cells
Fast-Twitch Fiber

Basolateral
Sarcolemma

N.D.
Limited Orthogonal Arrays

Parietal Cells Chief Cells

Basolateral

N.D.

Epithelial Cells

Basolateral

N.D.

Epithelial Cells

Basolateral

N.D.

Epithelial Cells
Glandular Cells Epithelial
Cells

Basolateral
Basolateral

N.D.
N.D.

Posterior Optic Nerve (ISH, IF,
IEM)
Inner Ear (ISH, IF, IEM)

Urinary mouse [137] rat
[138, 139, 141]
Respiratory human [142] rat
[138]

Muscular human [143] mouse
[137, 143] rat [139, 143]
Digestive human [144] Rat
[138, 139, 145]

Integumentary mouse [146]
rat [139]

Kidney Medullary Collecting
Duct (IEM, IB, IHC, IF)
Ciliated Ducts of Bronchi (IF,
IHC)
Acini of Bronchi Submucosal
Glands (ISH)
Trachea (IHC)
Skeletal Muscle (IF, IEM, RTPCR)
Stomach (IHC)
Villi of Distal Large Intestine
(IHC)
Salivary Gland Excretory Duct
(IHC)
Liver Bile Duct (RT-PCR, IB)
Lacrimal Gland and Excretory
Duct (IHC, IF)

Astrocytes

a. IF: immunofluorescence, IEM: immunoelectro microscopy, IHC: immunohistochemistry, RT-PCR: real-time polymerase chain reaction, IB:
immunoblot
b.N. D., not determined

lamic nuclei and in the subfornical organ, AQP4 is not
localized to one aspect of the membrane, but rather distributed [16]. AQP4 is expressed in situ in LPS-activated
microglial cell (monocytic origin) membranes [18].
While not technically in the CNS, retinal astrocytes
(Müller cells) have polarized expression of AQP4 with
high levels seen in end-feet membranes that oppose the
vitreous body or blood vessels but either reduced or no
expression on non-end-feet membranes and microvilli,
respectively [19]. Orthogonal arrays of intramembranouse particles composed of AQP4 are expressed in
fibrous astrocytes that associate with optic nerves [19].
The distribution of AQP4 is compartmentalized with endfeet membranes having high expression, while the membranes facing the nodal axolemma have lower expression.
In the perinodal processes, AQP4 is preferentially
expressed in the membrane opposite from the nodal
membranes. AQP4 is also expressed in the optic nerve
head which is unmyelinated.

Different isoforms of AQP4
Aquaporin 4 exists as two major isoforms (M1 and M23)
in rat and human astrocytes and some epithelial tissues
[20-22]. The M1 and M23 isoforms differ by 23 amino
acids at the N-terminus depending on which methionine
is used to start translation [20]. Based on algorithm analysis of the AQP4 sequence, the membrane topology of
AQP4 has been proposed [23] to have three extracellular
loops (A, C, and E) that connect the 6 alpha helices that
span the membrane (Figure 1). Freeze-fracture data of
AQP4-containing membranes, along with the identification of AQP4-specific antibodies in NMO patients that
bind extracellular AQP4 support the notion that parts of
AQP4 are accessible on the outside of the cell [7,21,24].
Recently, the structure of rat AQP4 has been more extensively analyzed and a model based on electron crystallography of double-layered, two-dimensional crystals has
been proposed [25]. The crystal structure of AQP4 suggests, in contrast to the algorithm analysis, that Loop E is
more intramembranous and involved in water transport
[25].
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Figure 1 4 is a type III water channel regulator with limited surface exposed residues
Aquaporin
Aquaporin 4 is a type III water channel regulator with limited surface exposed residues. AQP4 has been cloned
from mice, rats, and humans. Algorithms predicted a type III transmembrane protein with intracellular n- and c-termini (left
panel shows topology). Resides predicted in the extracellular loops are shown in one letter code. Residues based on the crystal
structure [25] that are predicted to be in the exposed extracellular loops are highlighted in either blue (Loop A) green (Loop
C), or orange-red (Loop E). Differences between rat (same as mouse) and human sequences in the exposed loops are noted by
single letter code in white.

Depending on the cell type, AQP4 can be expressed on
basolateral, apical or at both membrane locations with
the AQP4 isoform and protein-protein associations dictating the localization. In CNS astrocytes, AQP4 is associated
with transmembrane proteins, α and β – dystroglycan (αdystroglycan can bind laminin), Dp 71 (a dystrophin isoform), and syntrophin [26]. Deletion of α-dystroglycan
did not reduce AQP4 expression in all end-feet membranes, as AQP4 labeling was retained in the end-feet that
impinge on the subarachnoidal space and in cells that line
the ventricles. These results differ from those obtained
using the mdx mice (dystrophin-null lacking all splice
forms) that do not express AQP4 in subarachnoid endfeet or cells that line the ventricles [27,28]. Deletion of αsyntrophin results in loss of AQP4 expression in astrocyte
end-feet but not in AQP4 expressing cells in the kidney or
osmosensitive regions of the brain [26]. α-dystroglycan
and laminin interactions are proposed to anchor the
astrocytic end-feet (Müller cells) to their perivascular location in retina [29]. Laminin interacts with dystroglycan, a
component of the multi-protein complex which, in rat
astrocytes, is localized at the same membrane regions as
aggregates of the membrane channel protein Kir4.1
(potassium inward rectifying) and AQP4 (M23 isoform)
[30].
Complex transmembrane, cytoskeletal and extracellular
matrix components (agrin, heparan sulfate proteoglycan;
laminin, extracellular matrix protein) regulate access of
AQP4 to the apical domain of astrocytes where different

lipid species and additional membrane proteins (e.g., K+
leak channels) share the "domain space" with complex
arrays of AQP4. These complex associations are considered essential for AQP4 function in astrocytes [31,32]. The
genetic ablation of α-syntrophin is not fatal to mice but
the loss of expression does influence AQP4 expression in
the CNS. AQP4 expression in endothelial cells (not a
major pool of AQP4 expression) is maintained while the
AQP4 in astrocyte end feet is lost [33].
A recent study indicated AQP4 was internalized following
overnight culture at 37°c. with NMO-IGG serum [34]. The
significance of this observation to pathogenesis of NMO
disease is moderated by the use of only the M1 isoform in
HEK cells that do not normally express AQP4. The influence on the architecture of AQP4 complexes by M23 and
other protein elements needs to be understood before the
role of anti-AQP4 antibody-mediated internalization of
M1 AQP4 can be linked to NMO pathogenesis [30,35,36].
It was recently reported that the presence of cysteine residues and thus the potential post translational changes
(palmitoylation) in M1 residues 13 and 17 of the N-terminus of AQP4 prevents formation of AQP4 arrays [37].
AQP4 homotetramers and arrays
The homotetramer structure for AQP4 is consistent with
the structure of other AQPs [20,25]. While AQP4 cannot
associate with other AQPs, it can form heterotetramers of
M1 and M23 [20]. The importance of the M1:M23 isoform ratio to function in situ is not known, but in cultured
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epithelial cells, large M23-based arrays were more efficient
at water transport than M1 AQP4 [38]. All of the heterotetramers of M1 and M23 are equal in water transporting
characteristics when expressed in Xenopus oocytes [20].
The isoform ratio of AQP4 greatly influences the orthogonal arrays of the AQP4 tetramers [21,39]. The M23 isoform is associated with 4–6 nM intramembranous
particles in arrays as large as 100 particles. In contrast, M1
tetramers, which are the same size as M23, are overwhelmingly (95%) found as single tetramers [39]. In the
tetramer model, individual AQP4 subunits are proposed
to interact with each other via residues (R108, G157,
W231 I239, Y250) in the H4 and H6 helices [25]. Quaternary interactions are possible between AQP4 molecules
within tetramers or between AQP4 tetramers on apposing
membranes thus potentially limiting access of some
AQP4 regions to AQP4-specific antibodies.
AQP4 structure, immunogenicity, and B cell epitopes
The initial HEK transfectants employed to define NMOIgG binding used "full-length" human AQP4 which is presumably the M1 isoform [7] that does not form arrays in
Chinese hamster ovary or epithelial cells [21,39]. Two
other studies by Takahashi and colleagues [40,41] also
used HEK cells expressing an unidentified human AQP4
isoform and supported the previous report of Lennon and
co-workers. This might have been a fortuitous design
allowing the identification of anti-AQP4-specific antibodies in NMO patient's sera. Alternatively, the use of M1
might overestimate the ability of anti-AQP4-specific antibodies to bind to structures composed of the M23 AQP4
isoform which is the predominant form found in astrocytic end-foot processes [42]. One study reported the use
of human AQP4 M23-transfected HEK cells to assess sera
from Japanese MS patients with optic-spinal and longitudinal spinal cord lesions [43]. The AQP4 staining in this
study was positive and intense for rat CNS tissue with sera
that Tanaka and co-workers considered positive for NMOIgG, but it was different in intensity and staining pattern
compared to the confocal images of Lennon and colleagues [7]. However, images with control sera were not
available so the issue of signal to noise could not be
assessed. In support of the capability of NMO-IgG to bind
arrays of AQP4 in situ are the early studies of NMO patient
sera that demonstrated positive staining of murine CNS
tissue [24] using fluorescence microscopy which does not
distinguish between isoforms of AQP4. Based on the quaternary structure of AQP4 in situ and its interactions with
other membrane structures it is difficult to envision a
model whereby all potential B cell epitopes would have
equal access to extracellular NMO-IgG. Expression of
AQP4 on the basolateral cell membranes versus apical cell
membrane could also moderate the availability of AQP4
targets for immune system effectors, especially AQP4-specific antibodies.

http://www.jneuroinflammation.com/content/5/1/22

Optic nerve and AQP4 distribution
Several studies have reported that in NMO, areas of CNS
inflammation correlate with the expression pattern of
AQP4 [44,45]. Classically, NMO targets the spinal cord
and optic nerves and spares the brain. However, since the
development of the NMO-IgG test, case reports of NMO
patients with lesions in the brain have expanded the clinical criteria of NMO to include lesions in the brainstem,
deep grey matter and cerebellum, areas that have relatively
high expression of AQP4 [46,47].

The access of serum components to CNS tissues is generally limited, but there are distinct anatomical locations of
the CNS where the BBB has reduced capability to moderate serum access. AQP4 is expressed by astrocytes that surround the optic nerve. The optic nerve head is an area of
the CNS where the BBB is more permissive [48]. It has
been noted that while patients with NMO can develop
ON and LETM simultaneously, they are generally displaced in time with ON being experienced first and LETM
presenting weeks to months later [8]. Is there something
about the tissue organization of the optic nerve cells that
express AQP4, the vascular structures associated with the
optic nerves, or the type of astrocytes (fibrous astrocytes)
associated with the optic nerves that result in ON as first
indicator of AQP4-specific antibody pathology?
The prelaminar region of the optic nerve head is an area of
the CNS that has a permeable BBB as evidenced by immunostaining for markers of intact BBB [49]. Tracer studies
using rhesus monkeys demonstrated that blood-borne
proteins can reach optic nerve axons through the border
tissue of Elschnig in the optic nerve head [50]. In this
study, access to the optic nerve head was localized at a barrier formed by glial cells in the tissue of Kuhnt at the edge
of the optic disc that prevented tracer access to the subretinal space. AQP4 is expressed in fibrous astrocytes that
impinge on optic nerves preferentially in the membrane
that face away from the nodal membranes. The localization of AQP4 on fibrous astrocytes might function to
spare the optic nerve from volume fluctuation under normal physiological conditions. Perhaps one of the reasons
that ON with anti-AQP4-specific antibodies might initially be more prevalent than LETM in NMO is that the tissues of the optic nerve are more sensitive to volume
changes induced by AQP4 dysfunction than other areas of
the CNS [19]. Tso and co-workers [50] also noted that the
pia and fibrous septa of the optic nerve showed no leakage. Thus if inflammation in NMO is related to accessibility of serum components across the BBB, the optic nerve
head should be preferentially affected compared to other
parts of the optic nerve.
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Spinal cord and AQP4 distribution
Analysis of AQP4 distribution in the human and rodent
spinal cord has been of major interest since the discovery
of the NMO-IgG. Aquaporin 4 (mainly the M23 variant)
is expressed in ependyma and astrocytes in association
with blood vessels or nerves [20,51] in both the gray and
white matter of rat spinal cord [51,52] and in glial cell
processes adjacent to the ependymal cells of the central
canal. In the white matter, fibrous astrocyte processes that
surround blood vessels are also positive for AQP4. The
AQP4 expressed in the spinal cord differs from other nervous tissue cells as it is rarely polarized in astrocytes. AQP4
was most strongly present in fibrous astrocytes of the two
most superficial lamenae (substantia gelatinosa) of the
dorsal horn of the spinal cord, but less noticeable in the
intermediate gray matter and in the ventral horn [51,52].

In NMO, the cervical and the upper thoracic spinal cord
segments are generally more affected and single longitudinally extensive lesions starting in the cervical spine and
reaching into the brainstem are thought to be specific for
NMO. The cervical cord is closest to the cervical lymph
nodes where priming AQP4-specific responses is likely to
occur. One animal model proposes that the cervical
lymph nodes play a major role in the transverse myelitis
associated with EAE [53]. It is unclear if similar mechanisms play a role in the pathogenesis of NMO.
Ependyma and AQP4 distribution
The ependyma is another region of the BBB where the diffusion of serum components into the CNS is possible. In
rodent and human brain, AQP4 is expressed in basolateral
domains of ependymal cells lining the ventricles and central canal of the spinal cord [52]. Ventricular ependyma
has been reported to more highly express AQP4 than
ependyma lining the central canal of the spinal cord [54].
Ependymal cells have direct access to CSF as they do not
have a basement membrane and do not express tight junctions, thus AQP4-specific antibodies in the CSF would
have relatively free access to their target [55]. However,
when anti-AQP4 antibodies are detected in the CSF of
NMO patients, the concentration is less than 1:500 compared to the serum. Astrocytic foot processes along the
pial lining also express high levels of AQP4. In a recent
review of NMO by Pittock [56], regions in the pia were
noted to have pathologic changes in seemingly random
areas. It is of interest to understand how the difference in
AQP4 expression of ependyma and pia-associated astrocytes contributes to the potential pathogenic role of
NMO-IgG.
Potential AQP4 B cell epitopes and relationship to
pathogenesis
B cell epitopes are molecular signatures, structures that fit
in the antigen binding site of antibodies. The antigen
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binding site of antibodies is composed of structural contributions from the antibody's heavy and light chains. The
variable immunoglobulin gene exons with the intrinsic
first and second hyper-variable regions along with the
third hyper-variable region, formed by the junction of the
variable, diversity, and joining sequence, can either be in
germ line (baseline binding affinity) configuration or can
have undergone somatic mutations that are selected for
improved binding to its B cell epitope. Antibody binding
sites can vary in their structure and can accommodate
small molecules or large protein such that the binding site
surface area can range from several hundreds to over a
thousand square angstroms. Resolution of the AQP4
structure provides evidence that both small defined B cell
epitopes and extended conformation epitopes are possible based on exposed amino acids (Figure 2). The surface
area of the top of the AQP4 molecule is on the order of 35
× 30 Å2, a size that could represent a conformational
epitope with contributions from several exposed loops of
AQP4. The extracellular loops that connect the various
helices of the AQP4 water channel are thought to be
exposed. However, Loop C, the longest loop, contains
many non-polar residues and the structure as presented by
Hiraoki and coworkers [25] is modeled as being recessed
in the center of the complex. The other loops, A and E are
smaller and contain several residues that are hydrophilic
and typical partners for H-bonding or salt bridge interactions that are important for antibodies binding affinity. At
issue is how many of the residues and if their corresponding site chains are exposed "around" the top of AQP4 as
potential B cell epitopes required for NMO-IgG binding
(Figure 3).
An initial mapping of NMO-IgG may provide some clues
as to the AQP4-associated B cell epitopes. Lennon and coworkers used mouse tissue as an antigen source for immunohistochemistry [24]. NMO-IgG binds multiple sites
including the abluminal face of microvessels, pia, subpia,
and Virchow-Robin sheath of fixed murine CNS sections.
This is important as the AQP4 sequence between mice,
rats, and humans differs within the exposed residues in
the middle of Loop A [25,57]. In mice and rats, Loop A
has 62S, 63E, and 64N, whereas in humans the residues
are 62T, 63E, and 64K. Thus the binding of human NMOIgG to murine AQP4 suggests at least three interpretations: 1) that Loop A is not a B cell epitope, 2) the changes
between rodents and humans do not affect antibody
binding if the loop A sequence is a B cell epitope., or 3)
the sequence changes do affect binding of anti-AQP4 antibodies, but other AQP4 epitopes are still available and
antibodies in polyclonal sera have enough reactivity to
AQP4 to be scored as positive for binding if one AQP4
epitope is compromised. The second interpretation would
suggest more defined linear sequences as B cell epitopes
that would be expressed in the A or E loop structures.
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Figureof2 rat AQP4
Model
Model of rat AQP4. The RasMol 2.7.2 program is available on the WWW and was used to manipulate the protein data base
file, 2D57 [25]. RasMol 2.7.2 is an updated version of RasMol 2.6 developed by Roger Sayle while at the Biomolecular Structures Group, Glaxo Wellcome Research & Development, Stevenage, Hertfordshire, UK. The left image shows both ribbon and
space filling motifs. The ribbons are the six alpha helices that span the plasma membrane. The c-terminal and n-terminal
domains were not part of the crystal structure but would be projecting downward from the red and blue helices, respectively.
The top of the molecule shown in space filling format represents three loops that are thought to be surface exposed: Loop A
(blue), Loop C (green) and Loop E (orange-red). The image to the right is the view of the top of AQP4 looking down its central
axis.

Other information on possible AQP4 B cell epitopes was
reported by Nagy and colleagues [58] who made monoclonal antibodies to rat AQP4 peptides. An IgM of low
affinity was made to residues 206–231 (VRGASMNPARSFGPAVIMGNWENHWI) which form part of the water
channel helix and Loop E (Figure 4). The AQP4 crystal
model suggests that only the N- and C-termini of the peptide 206–231 are surface exposed and thus residues able
to form a B cell epitope might be limiting (Figure 4). This
B cell epitope is largely located on the lateral side of the
AQP4 model and thus accessibility concerns in situ need
to be addressed. We have recently demonstrated that antibodies raised in mice to this peptide bind human M1 and
rat M23-based arrays of AQP4 in transfected HEK cells
(unpublished observations, WF, Wade).

Clonal expansion of higher affinity AQP4-specific B cells
and activation or immune deviation due to AQP4-specific
T helper (Th) cells might reflect the time interval between
ON and LETM. Does affinity maturation of the anti-AQP4
(B cell or T cell) response have to occur for AQP4-specifc
antibodies to bind more inaccessible arrays of AQP4 on
astrocyte foot processes in the spinal cord? Perhaps ON
can be more readily induced by lower levels of effectors,
NMO-IgG and AQP4-specific T cells as fibrous astrocytes
cell might be more sensitive to anti-AQP4 antibody than
astrocytes in the spinal cord.
In the MOG-mouse TCR transgenic model of ON a related
question is apparent – why do MOG-specific transgenic
TCR mice only developed ON and not EAE. Interestingly,
treatments to induce changes in the BBB increase the manifestation of ON, but not of EAE, suggesting that the access
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Figure 3B cell epitopes of AQP4
Potential
Potential B cell epitopes of AQP4. The top two panels represent a side view (left image, Loop E facing viewer; right image
Loop A to the left) of AQP4 with amino acid residues shown in helical, space-filling, or ball and stick format. The space-filling
format represents the proposed extracellular loops (Loop A, blue, Loop C green, and Loop E orange-red). Ball and stick motif
represent amino acids within the loops that are potential antibody contact residues because of O (red) or N (blue) atoms available for H-bonding or salt-bridge interactions with anti-AQP4-specific IgG1. The middle panel is the top view of AQP4 with
formatting the same as described for the top two images. The bottom set of images has been restricted to show only the
loops. This view clearly shows the lateral projection rather than upward along the long axis of AQP4 of side-chains of amino
acids that could interact with anti-AQP4-specific antibodies (left image, Loop E facing the viewer; right image, Loop A facing
viewer). The amino acids in ball and stick representation are: Loop A, S62, E63, N64; Loop C, H151, N153, T155; Loop E,
N226, E228, H229.
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Figure 4
Immunogenic
peptide of AQP4
Immunogenic peptide of AQP4. The space filling motif on the left shows the helices from the top of the AQP4 molecule.
The white residues are amino acids 206–231 with several shown in CPK format that highlights oxygen (red) or nitrogen (blue)
atoms that might be available for interactions with antibody combining sites. The residues in white on the bottom of the figure
are 207, 208 while those on the top represent 216–231 with 224–229 in CPK format. In residues 224–229, M224, G225,
W227, and E228 for a cluster of residues that have multiple atoms available for H-bonding. The image on the right is rotated
90° relative to the image on the left.

of MOG-activated T cell to the spinal cord or brain is not
sufficient to cause EAE. Bettelli and coworkers [59], who
developed the MOG-ON model, speculated on the role
different concentrations of the autoantigen peptide, the
type of autoimmune peptide, the background genetics,
and tissue localization of the target antigen in explaining
the localized inflammation in this model. Other MOGmodels readily induce EAE indicating MOG-specific T
cells can be pathogenic.
Pathology of human NMO – then and now
There are multiple descriptions in the 19th century medical literature of the clinical manifestations of patients with
a disease characterized by unilateral or bilateral loss of
vision and myelitis [1]. Devic and Gault are credited with
the development of the criteria for a diagnosis of Devic's
disease. The early Devic's diagnostic criteria based on
autopsy were as follows: a macroscopically normal brain
with severe demyelination in the spinal cord and optic

nerves, cavitating lesions in the white or gray matter,
necrosis, blood vessel wall thickening, lymphocyte infiltration, but no significant neutrophil or eosinophil infiltration, which were only later observed by recent autopsy
of NMO patients [12,60]. One must be careful of over
interpreting the early literature because of the potential
for multiple causal events that resulted in either a clinical
or autopsy diagnosis of Devic's disease. The limited
number of reported case studies is also problematic for
determining the extent of the clinical picture of Devic's
disease in the last two centuries.
Since the discovery of the association between NMO-IgG
and Devic's disease, NMO has replaced the name of
Devic's disease and the criteria have been refined and
extended to include assessment of MRI imaging of the spinal cord and brain [61]. MRI of the brain should be inconsistent with multiple sclerosis and MRI of the spine
should show a contiguous extensive lesion more than 3
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vertebral segments in length in the setting of myelitis. In
addition, the presence of NMO-IgG was added as an additional supportive criterion for a diagnosis of NMO [62],
but is not required for the diagnosis.
The recent NMO literature indicates NMO can be either a
fulminating monophasic disease (20%) or more typically
one that is polyphasic (80%), with long term survival
being related to the number of attacks in the early period
after the initial event. Current therapies include glucocorticoids, azathioprine, plasmapheresis, intravenous immunoglobulin, and anti-CD20 monoclonal antibody
treatment [63-67]. It is unclear how aggressive modern
drug treatments along with plasma exchange and immunosuppression have modified the natural course of disease. Therapies that are effective in NMO patients are
those that, modify inflammation (gene activation events),
reduce lymphocyte proliferation, remove serum immunoglobulin and other components and in the case of the
anti-CD20 monoclonal antibody, kill pre-B cells, mature
B cells, and plasmablasts, but not lymphocyte stems cells
or plasma cells.
Biopsy and post-mortem autopsy pathology shows a characteristic pattern in CNS tissue of patients with NMO. In
addition to demyelination, NMO lesions are necrotic and
infiltrated with neutrophils and eosinophils. Complement and immunoglobulin deposits of types IgM and IgG
are found in a vasculocentric pattern that mirrors that
expression pattern of AQP4 in normal appearing white
matter [12]. Unlike MS in which AQP4 expression is upregulated in actively demyelinating plaques, NMO lesions
show a defining loss of AQP4 immunoreactivity. Even in
patches of so-called normal appearing white matter where
there is no other evidence of inflammation, AQP4 expression has been shown to be reduced. These characteristics
of NMO lesions are typical of all NMO lesions including
spinal cord and optic nerve most commonly, followed by
brainstem, cerebellum and cerebral cortex [68].
Another aspect of the modern diagnosis of NMO is the
analysis of CSF. Case reports and retrospective studies
indicate that oligoclonal banding can be found in NMO
patients, but at a much lower frequency than that found
in MS patients. The intrathecal IgG also tend to disappear
as NMO patients progress in treatment or disease [69,70].
Another feature of intrathecal antibodies of MS patients is
the tendency to have polyclonal specific responses to viral
antigens which is rarely found in NMO patient CSF [71].
It would be of interest to know if increased pleocytosis
noted in the more recent clinical work-ups was also
present in patients in the late 1800s and early 1900s [72].
Although detection of NMO-IgG in CSF is rare, CSF of
NMO patients, on average 4 years into what was character-
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ized as aggressive disease, were found to contain antiMOG antibody (IgM and IgG) cells, as well as mononuclear IL-5, IL6 secreting cells [10]. Eotaxin-2 and Eotaxin3, which are selective chemotactic factors for eosinophils,
and eosinophil cationic protein were higher in NMO
patient CSF than in normal CSF. The elevation of these
molecules was not specific to NMO as other neurologic
conditions have elevated eosinophil chemotactic factors
in the CSF.
NMO pathogenesis
Wingerchuck and co-workers at the Mayo Clinic proposed
a model that featured the anti-AQP4 antibody and how it
might be pathogenic [5]. They indicated that the pathogenic anti-AQP4 antibody binds to the extracellular component of the AQP4 protein and induces a reversible
internalization of the AQP4-IgG complex. The immunopathology aspect of the model is well-conceived and
possible. In this model, the authors leave out the role of
AQP4-specific B and T cells which certainly are part of the
immune response to AQP4.

The incomplete nature of negative selection of self-reactive B cells in the bone marrow or induction of anergy in
the peripheral B cell pool can result in a very high percentage of the B cell in the periphery with the capacity to
secrete autoantibodies. It is very likely that the normal
human B cell repertoire includes AQP4-specific B cells. B
cells can be non-specifically activated by infection or
inflammatory conditions that provide the cytokine milieu
and membrane proteins which can sustain B cell survival
and which can enhance their survival and selection. If
these cells enter the germinal center, they can undergo
somatic mutation and isotype switching of their low affinity IgM to high affinity IgG. The predisposition toward
autoimmunity is also associated with conditions that
allow survival of B cells with unwanted specificities [73].
Thus given the multiple means to push an existing B cell
repertoire to secrete autoantibodies (including NMOIgG), it is necessary to have a better understanding of the
tissue expression and the regulation of AQP4 in those tissues so that initiating and amplifying events in AQP4-specific T and B cell activation can be followed. The other
reason to understand this issue is related to the potential
pathogenicity of NMO-IgG antibodies which is probably
limited by the isotype, as IgM and IgA have more limited
access to tissue parenchyma than IgG. Further, not all cells
that express AQP4 exhibit pathologic changes in NMO
patients. The reason for this is not known, but may be
related to the access of expressed AQP4 in organs and tissues such as in kidney and gut epithelia to serum components or the association of AQP4 with other membrane
proteins.
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HLA-restriction, AQP-4 specific T cells, and NMO
NMO is not a common (1%) demyelinating disease of
Caucasians being more common in East Asians and other
non-white populations [74]. There is a current debate as
to whether NMO and Asian MS are the same disease. The
finding of NMO-IgG in a large percentage of Asian MS
patients substantiates this perspective [24,43,75]. The
genetic link for these differences is not known but if presentation of self antigen is part of the mechanism leading
to NMO, MHC genotype would be important and perhaps a distinguishing feature. This genetic link may be
linked to other factors which influence B cell survival,
cytokine production, MHC-based antigen presentation, or
target antigen regulation.

It seems reasonable to hypothesize that AQP4 specific T
cells are present in patients with NMO-IgG as AQP4 is a
protein antigen that requires T cell help for induction of
AQP4-specific B cells. In addition, the isotype (IgG1) of
AQP4 antibodies is associated with germinal center reactions, another component of an immune response that
involves T cells. A MHC class II linkage (HLA,
DPA1*0202; DPB1 0501; reactive with myelin basic protein) has been identified in patients (90%) with Asian MS
that some consider NMO; however the high expression of
this HLA type in Asians tempers the initial interpretation
of a causal link between HLA type and disease [76]. The
cognate antigen for the Asian MS group was mainly MOG,
with some reactivity to other oligodendrocyte antigens.
AQP4 T cells were not examined by the screening method.
Another group reported the severity of debilitation of
NMO patients correlates with the increased frequency of
Vβ 7 and Vβ 13 [one of the chains forming the antigen
specific T cell receptor (TCR)] expressing T cells in CSF of
NMO patients [77]. A close examination of ON and LETM
patients for HLA type and AQP4-reactive T cells should be
a priority. If they are present, then it is important to know
if the T cell effector phenotypes mediate lesion differences
(ON and LETM versus NMO). It would be interesting to
know if ON and LETM patients who do not go on to
develop NMO have a different AQP4-specific TCR and T
helper (Th) cell profile than those who develop NMO.
Priming of AQP4-specific B and T cells
A universal tenet of the immune response to MHC-associated antigen (self or non-self) is that antigen needs to be
recognized in the context of co-stimulation, a requirement
for priming antigen-specific T cells. Initial recognition and
priming of lymphocytes specific for protein antigens is
accomplished by professional antigen presenting cells
(APC) such as, dendritic cells (DC), B cells, and macrophages. Immune responses are dependent on lymphocytes that express antigen-specific or antigencrossreactive TCR and BCR interacting with the APC they
encounter while trafficking in the secondary lymphoid tis-
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sue. Priming is the initial recognition that results in clonal
expansion of naïve B and T cells and then effector and
memory cells. During infection, the type of cell death
(apoptosis or necrosis) of AQP4-expressing cells is important for priming AQP4-specific-T cells. If carrier epitopes
(TCR epitopes) are provided by pathogen proteins,
inflammation with polyclonal conditions could enhance
the AQP4 specific B cells entry and maintenance in the
memory pool.
The tissue source of AQP4 might be important for the efficiency and frequency of priming of AQP4 specific B and T
cells. AQP4 is expressed within and outside the CNS of
humans, rats, and mice (Table 1). There is cell death in the
CNS and trafficking of DC-like cells within the CNS resulting in tissue debris draining ultimately into cervical
lymph nodes [78,79]. Microglial cells are also known to
express class II restriction elements and present antigen in
a manner that can moderate or enhance a pathogenic
immune response. Their role in priming naïve AQP-4-specific T cells in draining lymph nodes is thought to be minimal, but they could clearly interact with AQP4-specific T
cells at the site of NMO pathology [80,81]. CNS antigens
can enter the periphery by drainage through tissue below
the cribriform plate and into the nasal mucosa [82,83].
Alternatively, perivascular CNS macrophages that survey
the CSF for soluble and tissue debris from effete membrane and exocytic processes can migrate to CNS draining
lymph nodes [81,82]. Migration of CNS macrophages to
cervical lymph nodes results in presentation of the peptide components of the gathered CNS species in association with MHC class II molecules resulting in
maintenance of peripheral tolerance of T cells if co-stimulation is not provided [83].
The hosts' genetics (HLA selection of T cell repertoire)
coupled with infectious disease or inflammatory history,
would contribute to events which either favor or not the
initiating events of AQP4-specific lymphocyte activation.
As AQP4 reactive B and T cells traffic between lymph
nodes, the initial priming could occur at either CNSdraining or non-CNS draining lymph nodes, but once
activated the normal steady state of presentation of
autoantigens by multiple APC (DC and macrophages
associated with the perivascular space, leptomeninges or
choroids plexus) microglia, or astrocytes could activate T
cells as they traffic in the CNS. Previous activation of T
cells in CNS draining lymph nodes could amplify the
AQP4 reactive lymphocytes and their ability to traffic into
the CNS. Activated AQP4-specific T cells would cause disruption of the BBB thus allowing increased concentration
of AQP4 antibodies and other immune system effectors to
enter the tissues where AQP4 is expressed on astrocyte
apical membranes. Further activation of the AQP4-specific T cells even in low numbers could sustain the BBB
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breach and recruitment of effectors that cause more
pathology with time.
Bacterial and viral infection can damage respiratory epithelial cells which express AQP4, thus providing conditions to enhance antigen presentation by mature dendritic
cells as well as obviating the influence of regulator T cells
which could otherwise play a role in the typical non-pathogenic responsive to AQP4. Because the potential for
simultaneous expression of AQP4 peptides, pathogenassociated peptides, and TLR agonists is possible the T
cells that provide help for AQP4-specific B cells, the T cells
do not have to be AQP-4 specific and could be pathogenspecific T cells. Another means to activate AQP4-specific B
cells is bystander activation of AQP4-reactve B cells by the
cytokine milieu and associate membrane changes of dendritic cells during infection or autoimmunity that enhance
B cell survival and differentiation. Once activated, AQP4specific B cells are very effective antigen presenting cells
and could be the important step in the subsequent activate of AQP4-specific T cells via BCR-internalized AQP4.
The scenario of AQP4-specific activation of B and T cells is
similar in autoimmune diseases. Salivary and lacrimal
glands express autoantigens associated with SS and can
also be disrupted by infection or autoimmune attack. As
salivary glands express AQP4, the initiating autoimmune
response to non-AQP4 antigens might liberate AQP4 that
because of intrinsic failures in immune regulation in
autoimmunity would facilitate AQP4 B cell activation and
survival.
Infection and autoimmunity can result in events that alter
the BBB and thus permit access of AQP4-specific antibodies and T cells to the CNS. Some cytokines, universal regulators of cells of the immune system, can affect the BBB
as well as the expression of glial cell-associated AQP4.
Interleukin 1β and interferon β up-regulate AQP on rat
astrocytes [84], whereas interferon γ(IFN-γ) but not Interleukin 1β or TNF-α increases expression of human astrocyte AQP4 in vivo [85]. The interaction between glial and
endothelial cells is critical for BBB function [86,87]. Conditions which activate these cells and cause upregulation
of AQP4 when the BBB function is compromised would
result in higher epitope density for anti-AQP4-specific
antibody binding that could disrupt function of any one
of the cells and thus lead to changes in water retention
which may be part of the initial pathology of NMO. It
would be interesting to determine if antibodies to Kir4.1,
an inward-rectifying potassium channel co-localized with
AQP4 on astrocyte foot processes are able to cause NMOlike disease.

http://www.jneuroinflammation.com/content/5/1/22

Does the Th cell have to be specific for AQP4 in order to
induce AQP4-specific antibodies
It is generally accepted that activated-antigen specific T
cells can enter the brain and cause disruption of the BBB
for CNS autoimmune disease. There are at least two antigens for which specific T cells might be relevant for NMO,
as both MOG and AQP4 antibodies have been detected in
CSF and sera of NMO patients. The CNS cells that express
MOG and those that express AQP4 differ. MOG or AQP4specific T cells enter the CNS and would recognize cognate
antigen presented by endogenous by APC in the CNS at
multiple locations. Microglial are capable of "cross-presenting" MOG and presenting endogenous AQP4. Macrophages and DC are associated with the perivasculature of
the pia which also contains AQP4-expressing astrocytes.
Thus there are at least two possible incipient antigens that
might be primary in the induction of NMO.

This scenario raises an important point: Is NMO a specific
disease (target and type of pathology) due to a specific
antigen such as AQP4? Alternatively, is NMO a syndrome
with distinct but multiple causes triggered by multiple distinct antigens that induce autoreactive T cells and high
affinity antibodies? These immune effectors might react
with several exposed CNS antigens and cause tissue damage or disruption of the astrocyte/glial axis that set the
stage for long term immune effector access and disease.
The answer to whether NMO is a specific disease, a syndrome, or subtype of MS awaits the identification of the
insipient autoantigens for both disease phenotypes.
Epigenetic events-major or minor role in NMO
Is there something special about certain types of neural
inflammation and subsequent expression of cellular antigens in the context of co-stimulatory molecules at the
astrocyte/endothelial cell interface resulting in antiAQP4-specific B cells whereby only a limited set of individuals go on to develop NMO? In the syndrome hypothesis above, it is likely that AQP4-specific B cells are readily
induced in certain infections but NMO does not result, or
is self-limiting as is typical for pediatric NMO patients.
Subsequent resolution of the infection and tissue damage
limits AQP4 exposure at non-CNS draining lymph nodes
and prevents the activation of AQP4-specific autoimmune
effector cells. Are recurrent or specific infections near the
neck and head where the draining cervical lymph nodes
have a higher concentration of AQP4 protein more likely
to be the priming event for ON or LETM? Once AQP4-specific B and T cells are activated, how does the constitutive
expression of AQP at leaky BBB contribute to pathogenesis? An animal model is required to address these types of
questions.
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Potential pathogenic role of AQP4-specific antibodies
The presence of myelin basic protein specific antibodies,
as well as other autoantibodies, in cord blood suggests
that the human immune system has multiple clones of B
cells early in life that could contribute to autoimmunity
[88]. The human B cell repertoire (germline) has B cell
clones that express a BCR reactive to AQP4 either as a bona
fide antigen or as a cross reactive species. NMO-IgG can be
associated with younger individuals [89,90] but is more
typically found in older individuals in their fourth decade
of life. Pathology associated with bacterial or viral infections can target organs/tissues that express AQP4 and thus
prime AQP4-reactive B cells if they are not clonally
deleted or anergized during tolerance induction.

Further studies are needed to prove the pathogenic role of
anti-AQP4 IgG1, whether it be singular, additive or synergistic with other antigen-specific effectors of the immune
system. NMO, ON, and LETM patients' B cells should be
positively selected and either immortalized or cloned as a
source of cells to screen for anti-AQP4 antibodies. IgM, as
well as isotype-switched antibodies specific for naturally
expressed AQP4, should be evaluated in more patients
with autoimmunity and NMO. The generation of these
types of reagents early in the disease presentation and during the progression of the disease would have several benefits. The nature of the Ig locus in human AQP4-specific B
cells could be evaluated and it could be determined
whether the anti-AQP4 IgG1 have germline sequences or
have somatically mutated sequences. If the latter occurs,
then the B cells have likely undergone germinal center
reactions signifying interaction with antigen-specific T
cells. Correlation of the affinity of anti-AQP4 IgG1 and
the B cell epitope targets of those antibodies on AQP4
should be useful as a means to further evaluate disease
progression or prognosis.
The presence of IgM, IgG, and complement cascade products in the pathology of NMO optic nerve and spinal cord
may represent non-specific antibodies as well as antiAQP4-specific antibodies. Human monoclonal AQP4specific IgG1 antibodies should be used to generate antiidiotype reagents that could be used to identify AQP4
IgG1 binding in situ of autopsy tissue. A practical advantage of the anti-idiotype reagent if they are of high enough
affinity would be imaging of patients tissues while they
are experiencing clinical symptoms as well as during the
period of remittance of the clinical disease. As a complement to determining how or if, anti-AQP4 IgG1 contributes to NMO pathology; anti-AQP4 antibodies need to be
evaluated with respect to their affinity, epitope specificity,
isotype or subclass, and ultimately pathogenic potential.
We need to know if a specific concentration or specificity
of anti-AQP4 antibodies is required to manifest NMO.
Similarly, we should try to understand the role of AQP4-
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specific T cells in inducing inflammatory disease of the
optic nerve and spinal cord.
NMO in association with other diseases
NMO-IgG has been found in patients with various infections and autoimmune disorders, as well as neoplastic,
conditions not typically consistent with induction of the
immune system against CNS AQP4. The autoimmune diseases associated with NMO can be either organ specific
(Myasthenia Gravis, MG) or systemic (Systemic Lupus
Erythematosus, SLE) but have a common characteristic of
the involvement of autoantibodies specific for a panel of
extracellular and intracellular antigens. Several reports of
thymoma (without Herpes simplex virus -2 involvement)
related NMO-like disease has been reported. One was
associated with anti-CV2/CRMP5 antibodies and another
MG [91,92].
Autoimmune disorders and NMO
Clinical signs of NMO or NMO-like disease have been
reported coincident with [93,94] or following symptoms
of SS [95,96]. Sjögren's Syndrome is an autoimmune disease characterized by inadequate tear and saliva production and a lymphocyte infiltration of exocrine glands,
especially the lacrimal and salivary glands, which express
AQP 5 on the apical membrane and AQP4 on lateral
membranes [97,98]. Sjögren's Syndrome patients typically have autoantibodies that bind the nuclear antigens
and RNA-binding proteins, Ro52, Ro60, and La48. In SLE,
immune complexes deposition can affect the skin, joints,
kidneys, lungs, nervous system, serous membranes and/or
other organs of the body whereby inflammation damages
membranes (lungs, kidney, nervous system) which also
can contain AQP4. Autoantibodies associated with SLE
typically bind ssDNA or dsDNA, DNA-associated proteins
(PCNA and histones), snRNAs, ribosomal P, and phospholipids. Clinical signs of NMO have been diagnosed
together with SLE [99,100] or years later [101,102]. Most
of the reported cases of SLE associated with NMO were
prior to the identification and use of NMO-IgG1 as a diagnostic tool. NMO-IgG1 is detected in most sera of patients
with concomitant NMO or NMO partial syndromes
together with SS or SLE, but not in sera of SLE or SS
patients that are not diagnosed with NMO [8,103]. In the
study by Pittock and co-workers, the limited patient base
who had SS or SLE, or both diseases predated the NMO
diagnosis by 1–8 years with a bimodal distribution of 1
year or ≥ 7 years [104]. They concluded that patients with
other autoimmune disorders who also test positive for the
NMO-IgG have manifestations of NMO superimposed on
their baseline autoimmune disorder. It will be important
to accrue more patients for these types of analyses to see if
progression is either fast or slow and if this relates to different types of anti-AQP4 antibody responses.
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Myasthenia gravis is an autoimmune disease that features
antibodies that bind the acetylcholine receptor in muscle
motor neural endplates thereby causing weakness (ocular,
bulbar, limb), and respiratory distress. It is interesting the
same multi-protein complex that associates with AQP4
and localized it to the membrane in astrocytes is also
involved with aggregation and localization of the acetylcholine receptor at the neuromuscular junction
[105,106]. Myasthenia gravis is the prototypic neuroimmunologic disease caused by a pathogenic antibody.
Autoimmune autonomic neuropathy is another neurologic disease that is likely to be mediated by a pathogenic
antibody [107] and NMO may be the third. An antibody
is classified as pathogenic if it meets 5 specific criteria
[108]. First, the antibodies should be present in a substantial fraction of patients with the disease. In studies of the
incidence of NMO-IgG in NMO, the range varies from
30–75%. Second, the antibody should bind to a specific
target. NMO-IgG has been shown to bind to AQP4 and
confirmed by several labs. Third, passive transfer of NMOIgG should reproduce features of the disease. Recall the
elegant experiments in MG where passive transfer of
human anti-acetylcholine receptor antibody caused disease in mice [109]. This has not been demonstrated in
NMO. Fourth, immunization with the relevant autoantigen produces a model disease in animals. This also has
not yet been demonstrated in NMO. Fifth, reduction of
the antibody should ameliorate disease. To date there has
been only a single study demonstrating the relationship of
titer to disease activity in an NMO patient [41].
While T cells are likely involved in providing help for production of autoantibodies, T-cell effectors are not associated with the pathology at postsynaptic neuromuscular
junctions [110], supporting the prospect that anti-AQP4specific antibodies could be pathogenic by themselves.
Cases of NMO diagnosed after onset of MG often had surgical intervention for thymoma [91] or thymus hyperplagia [111,112]. Forty percent of MG patients who were
evaluated for NMO-IgG were positive and two female
patients with NMO and MG were of Japanese ancestry
[111,112]. There is also a unique case report of an individual diagnosed with MG and NMO together years after
onset of SLE in addition to Grave's disease [112].
Infections and NMO-IgG
Many NMO patients report a preceding bacterial or viral
infection of different tissues, especially epithelial tissues,
prior to the onset of neurologic symptoms. NMO following pulmonary tuberculosis in patients from Cape Town,
South Africa [113-116] or mycoplasma pulmonary infections [117,118] have also been reported. Mycobacterium
and Mycoplasma sp. are known to express proteins that
have homology to AQPs [119]. A possible link has been
suggested between mycoplasma infections and TNFα,

http://www.jneuroinflammation.com/content/5/1/22

eicosanoids, and nitrous oxide triggered by Mycoplasma
sp. stimulated rat glial cells [120].
We searched the protein data base for protein homology
of the extracellular loops of AQP4. We found aquaporins
that Mycobacterium and Mycoplasma sp. express that
have similar residues to human AQP4 (unpublished
observations, Wade WF). Syphilis was thought to be
causal in a case report of and NMO without anti-AQP-4specific antibody [121]. In many of the cases of parainfectious NMO the presence of AQP4-specific antibodies is
not reported and some CSF profiles are not consistent
with NMO. However in some reports, MRI analysis (spinal cord) and clinical presentation are consistent with a
diagnosis of NMO.
Viral infections can often lead to ON. While not common,
NMO has been associated with HIV-1 infection in an African woman [122]. Another viral disease that can precede
NMO is dengue fever, which is prevalent in Brazil. NMO
or NMO-like symptoms following within a week or so of
viral infection was reported in a young female patient of
Japanese ancestry, while a 58-year-old man of Japanese
ancestry who also lived in Brazil was admitted to hospital
suffering from acute disseminated encephalomyelitis
(ADEM) after Dengue virus infection [123,124]. Several
different types of herpes infections (Cytomegalovirus,
Varicella) have been reported in patients with apparent
NMO [125-127]. The Cytomegalovirus patient who was
negative for NMO-IgG was a male who switched gender,
but it was not reported if hormone therapy was in place.
Female sex hormones are known to be able to affect B cell
biology and thus enhance the possibility of autoantibody
production [128]. Both of the Varicella patients were
female, one black and one Bangladeshi whose ethnicity
was not reported. With the new criteria for NMO it would
be very useful to track such infection related cases with
respect to anti-AQP4-specific antibody at the time of presentation after recovery or at autopsy. HLA-tissue typing of
the rare cases of infections that lead to NMO would be of
value as well.
Animal models of NMO-like diseases
Currently there are no animal models that feature AQP4
as the autoantigen that induces NMO-like pathology. It is
important to initiate development of an AQP4-based animal model of NMO to determine whether AQP4 is the
autoantigen required for NMO, either due to AQP4-specific T and B cells, specific AQP4 antibody or both cellular
and soluble effectors. We recently induced high titer
antiserum in mice to the rat 206–231 sequence of the E
Loop of AQP4 (unpublished observation, Wade WF).
Pooled sera from the AQP4-peptide immunized mice
bind the M1 human isoform and the rat M23 isoform of
AQP4 in HEK cells. Similarly, an AQP4 peptide (QTKG-
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SYMEVEDNRSQVETED, amino acids 272–291) from rat
AQP4's cytoplasmic domain, that is predicted to be an
autoimmune T cell target, was immunogenic in rats
(unpublished observation, Graber DJ, Hickey WF). Investigators at Johns Hopkins University have induced high
titers of autoantibodies to extra- and intracellular AQP4
peptides in Lewis rats although it has been more difficult
in C57 mice (unpublished observation, Levy M, Kerr D).
Thus the target sequences within AQP4 with which to
investigate NMO are beginning to be realized and thus
soon will be available to develop AQP4 animal model
based on those enumerated and developed for MOGinduced CNS autoimmunity.
There are multiple rodent (mice or rat) models of EAE
which can be induced with myelin antigens. The value of
the animal EAE models which are based more on the
pathology of MS than NMO is the mechanistic information they can provide. One of these models demonstrates
that the presence of spinal cord pathology can be dependent on the presence of CNS antigen-specific autoantibodies [129,130]. The induction of these antibodies can be
regulated by the form of the autoantigen or the genetics of
the host. Tissues that are the targets of pathology in EAE
and NMO can overlap but the details of the immune
response and the autoantigen can shape the final effector
phases. The differences in EAE and NMO pathology
should not be used to eliminate the investigation of an
EAE-NMO model system that might highlight common
mechanisms relative to antigen-specific T cells and
changes in the BBB that can enhance the pathogenic
potential of autoantibodies.
In two rodent models of MOG-induced disease, there is
NMO-like pathology implying that an AQP4-based system could be developed [129-131]. The similarity of the
AQP4 protein sequence between humans and these
rodents, and the fact that human NMO-IgG binds murine
CNS AQP4 further substantiates the feasibility of developing an AQP4-based rodent model of NMO. In the case of
mice, the established method of generating transgenic
animals with AQP4-specific BCR and TCR would be a
benefit. The availability of various immune mice that have
select immune regulators genetically deleted (knockout
mice) would help define the parameters that can be
enhance the penetrance of the disease as it is only partial
in the murine double, transgenic MOG-antigen receptor
mice. Rats have long been used as CNS autoimmune
models in part because of the size of their target organ,
which along with the well-described role of rat AQP4 in
rat CNS physiology would be an argument for using rat as
an experimental host. The other advantage of the BN
strain for the basis of an AQP4 NMO model is the disease
manifests (60%) within weeks of inoculation and impor-
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tantly, NMO-like pathology can be induced by the naive
B and T cell repertoire.
Mouse model – MOG-specific BCR transgenic
There is a murine model wherein the mice spontaneously
develop ON [59]. This model is based on transgenic
expression of a TCR specific for MOG, peptide 35–55.
Transgenic MOG-specific CD4 T cells, without prior antigen activation causes ON in 30% of the mice. Immunization of mice with MOG 35–55 peptide (10 or 100 μgs) in
complete Freund's adjuvant without pertussis toxin
enhanced the percentage (55% and 78%, respectively) of
mice with ON [59]. The MOG peptide can activate CD4 T
cells and is long enough to contain B cell epitopes. However, neither the presence of anti-MOG 35–55 antibodies
in these mice nor that of Anti-AQP4 antibodies was
reported.

A later study that used the MOG 35–55 specific TCR transgenic mice examined the retinal ganglion cell damage
induced by spontaneous or pertussis toxin-induced ON
[132]. This study extended the first report by showing that
pertussis toxin enhanced the development of ON. Further
this group showed that inflammation preceded retinal cell
loss, suggesting that increased access of T cells to antigen
or activation of MOG-specific T cells or both in the optic
nerve resulting in lesion development in a larger percentage of mice. An issue that was not addressed by either
study was which cell type was the in situ APC (microglia,
macrophages or dendritic cells) in the optic nerve tissue.
CD4 T cells are typically restricted to MHC class II which
is not normally expressed on oligodendrocytes, the cell
type that expressed MOG.
MOG-specific BCR and TCR double transgenic mice
Bettelli and coworkers [129] and Krishnamoorthy and
colleagues [130] modified the MOG TCR model by crossing these animals to a line of animals with a rearranged B
cell receptor (BCR) specific for a conformational epitope
of MOG. In human MS, MOG-specific antibodies can be
either specific for conformational or linear determinants,
but the conformational antibodies are those associated
with pathology [133]. Mice that express both a BCR and a
TCR specific for MOG epitopes develop inflammation of
the spinal cord. BCR MOG-specific transgenic mice or
those mice crossed with a non-MOG specific TCR transgenic mouse line that have MOG specific IgM do not have
NMO-like pathology [130]. The co-expression of MOGspecific BCR and MOG-TCR transgenic lymphocytes
results in isotype switching of the MOG antibodies to
IgG1, which in mouse is related to a different Th-profile
than that associated with the human AQP4 IgG1 subclass.
In the double transgenic, IgG1 and not IgM is correlated
with disease. Increased activation of MOG-specific T cells
was thought to be due to enhanced antigen presentation
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by MOG-specific B cells, while the role of isotype-switching was not investigated [130]. The CNS pathology of the
double transgenic was proposed to be NMO-like because
the lesions were in the optic nerve and spinal cord as seen
in NMO patients. However the perivascular IgM, IgG, and
complement products associated with human NMO were
not present in the double transgenic model, nor were antiAQP4 antibodies [130]. The inflammatory cell types seen
in NMO, mainly eosinophils with some neutrophils,
[10,12] were generally absent in the cellular infiltrates
reported by Krishnamoorthy and coworkers [130]. Thus
the double MOG transgenic mice do not reproduce NMO
pathology but do provide a clear link to understanding
how antigen specific B cells can play a role in regulating
the pathogenicity of autoreactive T cells.
Rat model-antibodies to MOG are important
The Brown Norway (BN) rat EAE model is particularly
instructive for thinking about the pathogenesis of NMO.
Immunization of BN rats with recombinant MOG protein
but not MOG peptides results in EAE [131]. In BN rats
anti-MOG specific T cells are not pathogenic compared to
Lewis rats. One of the reasons for this is thought to be the
type of Th response. A Th 2 response is more likely in BN
rats than in Lewis rats, which have fulminate EAE after
immunization with MOG peptide and adjuvant [134].
The differences in the genetics that may cause this are
beginning to be unraveled and MHC as well as other intragenic MHC or linked genes, may play a role. Of special
note is that in BN rats, the manifestation of EAE is
dependent on high titers of antibody to MOG. Either by
passive or active immunization both T cells and B cells
specific for MOG result in immunopathology in the spinal cord and optic nerves characterized by the accumulation of neutrophils and eosinophils.
Approachable questions based on a small animal NMO
model
It seems clear that AQP4-specific T cells are activated in
NMO. Lymphocyte accumulation in the lesion area of
early NMO patients were not characterized, but the fact
that activated T cells are a major cause of changes in the
BBB and the fact that T cell help is required for isotypeswitching to protein antigens, suggest that AQP4 specific
T-cells are present. What they do in NMO is not known
and might be only important in isotype switching. Expression of class II molecules is a potential issue that might
mediate the choice or rats over mice, as rats express class
II on non-professional antigen presenting cells in a similar
manner to humans. We do not know how efficient
murine and rat MHC class II are at binding AQP4 peptides
and activating AQP-specific T cells. The activation of T
cells is dependent on the type of APC, the cytokines they
can make, and the MHC/peptide density, both of which
can be reflected in the Th-profile of the T cells that are
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selected and expanded. The quality of antigen presentation is also important for selection of most fit (higher
affinity for MHC/peptide) antigen-specific T cells. If the
rodent MHC molecules are limiting, then transgenic mice
expressing human HLA DPA1 0202/DPB1 0501 might be
required to induce T cells that respond to AQP4 and thus
cause disease. Clearly the types of experiments that investigate the role of both T and B cells AQP4-specific effectors
will be important.
Once the AQP4 model is established, investigations into
the parameters that can affect disease manifestations will
be decisive in understanding events that can contribute to
humans developing NMO. Experimental designs to
address these questions are not approachable in humans.
An AQP4 small animal model will permit investigators to
examine the following experimental questions: 1) What
peripheral or CNS "event" can lead to anti-AQP4 immune
responses, and 2) what AQP4 specific immune responses
are shaped by infection or underlying autoimmunity that
result in NMO? 3) Has the current therapy for NMO
changed the immunophenotype of the pathology? 4)
Does anti-CD20 therapy which removes anti-AQP4 specific B cells but does not quantitatively deplete AQP4-specific antibodies work because AQP4-specific T cells are no
longer activated?
It would be very interesting to determine if a particular
isotype of rodent anti-AQP4 antibody (IgG2a in the
mouse is equivalent to human IgG1) is pathogenic. The
isotype may not be as relevant for pathogenesis as the
antibody's concentration and affinity which could be easily tested in the rats with monoclonal reagents. The role of
anti-AQP4 specific antibodies and B cells versus the individual components could be tested with passive transfer
experiments. Immunization of AQP4 into mice with
underlying immune dysfunction (enhanced B cell activating factor expression, mutations in CD95 or its ligand)
might be a useful approach to study enhanced survival of
AQP4-specific B cells and thus to determine if NMO disease manifestation is more frequent.

Conclusion
The available data does not show a clearly defined mechanism explaining the association of NMO-IgG and NMO.
The current paradigm of CNS autoimmunity includes activated, antigen-specific T cells as the principle means to
moderate the BBB. It is critical to determine if there is a
pathogenic role for NMO-IgG in NMO. A potentially
unique mechanism whereby anti-AQP4 antibodies initiate pathology by themselves is that they have access to certain areas of the BBB that are considered more permeable
and thus can initiate damage to a critical 'gatekeeper"
(astrocytes) that normally preclude access of other
immune components to the CNS. AQP4 expression is ele-
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vated in many conditions of CNS inflammation and diseases such as spongiform encephalopathy, Alzheimer's,
stroke and others which do not have an infection or
autoimmune component. Perhaps the importance of
AQP4 for regulating brain edema suggests that when its
function is interrupted and the BBB is compromised,
immunopathology ensues. Several different but perhaps
limited specificities of autoantibodies targeting antigens
at specific sites (optic nerve and spinal cord) high in
AQP4 expression and a structural BBB that is intrinsically
more permissive to serum proteins may be required for
NMO. If the autoantibodies are not pathogenic per se, it
may be that the ability of self-reactive B cells to capture
their cognate antigen and, in the case of AQP4 or MOG,
present antigen to normally non-reactive MOG or AQP4specific T cells, instigates NMO. There are multiple pathways whereby AQP4 from peripheral and CNS sources can
induce AQP4-specific T and B cells. Inflammation and
underlying autoimmune dysfunction can enhance AQP4
expression, prime antigen-specific lymphocytes, and
establish conditions to sustain autoimmune responses.
An AQP4-based animal model needs to be developed to
address these issues and determine if AQP4-specific antibodies represent a novel means to cause CNS immunopathology similar to NMO disease in humans. We need to
know if AQP4-specific T cells are dispensable or if they are
part of a more complex scheme of pathogenesis that
includes anti-AQP4-specific antibody which is consistent
with the general paradigm of antigen-specific T cells being
important to CNS autoimmunity.
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